Lv11
40 积分 2026-04-06 加入
Additive Effekte durch die Kombination von Finerenon und Empagliflozin bei chronischer Nierenerkrankung und Typ-2-Diabetes? – Ergebnisse des CONFIDENCE Trials
12分钟前
求助中
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
1个月前
已完结
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial
1个月前
已完结
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
1个月前
已完结
Dapagliflozin in acute myocardial infarction with type 2 diabetes: a randomized clinical trial
1个月前
已完结
Dapagliflozin in acute myocardial infarction with type 2 diabetes: a randomized clinical trial
1个月前
已完结
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
2个月前
已完结
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2个月前
已完结
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
2个月前
已完结
Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes
2个月前
已完结
皖公网安备34019202002308
